KR20150130389A - 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 - Google Patents

티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 Download PDF

Info

Publication number
KR20150130389A
KR20150130389A KR1020157027855A KR20157027855A KR20150130389A KR 20150130389 A KR20150130389 A KR 20150130389A KR 1020157027855 A KR1020157027855 A KR 1020157027855A KR 20157027855 A KR20157027855 A KR 20157027855A KR 20150130389 A KR20150130389 A KR 20150130389A
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
group
cycloalkyl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157027855A
Other languages
English (en)
Korean (ko)
Inventor
졸란타 그렘벡카
토마즈 시에르픽키
드미트리 보르킨
제이 헤스
둑신 선
크시아오킨 리
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 미시간
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 미시간 filed Critical 더 리젠츠 오브 더 유니버시티 오브 미시간
Publication of KR20150130389A publication Critical patent/KR20150130389A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157027855A 2013-03-13 2014-03-10 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 Withdrawn KR20150130389A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780099P 2013-03-13 2013-03-13
US61/780,099 2013-03-13
PCT/US2014/022750 WO2014164543A1 (en) 2013-03-13 2014-03-10 Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20150130389A true KR20150130389A (ko) 2015-11-23

Family

ID=51529943

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157027855A Withdrawn KR20150130389A (ko) 2013-03-13 2014-03-10 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법

Country Status (11)

Country Link
US (4) US9216993B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968342B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016512514A (cg-RX-API-DMAC7.html)
KR (1) KR20150130389A (cg-RX-API-DMAC7.html)
CN (1) CN105188705A (cg-RX-API-DMAC7.html)
AU (1) AU2014249233A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015022602A2 (cg-RX-API-DMAC7.html)
CA (1) CA2904612A1 (cg-RX-API-DMAC7.html)
IL (1) IL241193A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015011576A (cg-RX-API-DMAC7.html)
WO (1) WO2014164543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013323360B2 (en) * 2012-09-28 2017-09-07 Cancer Research Technology Limited Azaquinazoline inhibitors of atypical protein kinase C
CA2904612A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
AR104020A1 (es) * 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
EP3302057A4 (en) 2015-06-04 2018-11-21 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
EP4643952A2 (en) * 2016-01-26 2025-11-05 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
ES2947636T3 (es) * 2016-03-16 2023-08-14 Kura Oncology Inc Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso
MY199965A (en) 2016-03-16 2023-11-30 Univ Michigan Regents Bridged bicyclic inhibitors of menin-mll and methods of use
KR20190015275A (ko) 2016-05-02 2019-02-13 더 리젠츠 오브 더 유니버시티 오브 미시간 메닌 억제제로서의 피페리딘
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
PL3468966T3 (pl) * 2016-06-10 2021-04-06 Vitae Pharmaceuticals, Llc Inhibitory interakcji menina-mll
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
LT3512857T (lt) 2016-09-14 2021-04-12 Janssen Pharmaceutica Nv Menin-mll sąveikos spirobicikliniai inhibitoriai
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CA3033020A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
EA039109B1 (ru) * 2016-12-07 2021-12-06 Кура Онколоджи, Инк. Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения
BR112019012106A2 (pt) 2016-12-15 2019-10-29 Janssen Pharmaceutica Nv inibidores de azepano de interação menin-mill
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
EA038388B1 (ru) * 2017-01-16 2021-08-19 Кура Онколоджи, Инк. Замещенные ингибиторы менина-mll и способы применения
CN110691779B (zh) * 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
WO2018183857A1 (en) 2017-03-31 2018-10-04 The Regents Of The University Of Michigan Piperidines as covalent menin inhibitors
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
AU2018389145B2 (en) * 2017-12-20 2023-02-02 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN110204552B (zh) * 2018-02-28 2021-08-17 中国科学院上海药物研究所 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
JP7239562B2 (ja) * 2018-03-30 2023-03-14 住友ファーマ株式会社 光学活性な架橋型環状２級アミン誘導体
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
CN112771055B (zh) * 2018-08-08 2023-10-20 住友制药株式会社 光学活性桥接哌啶衍生物
US20210353610A1 (en) 2018-10-03 2021-11-18 The Regents Of The University Of Michigan Small molecule menin inhibitors
US12065430B2 (en) 2018-10-26 2024-08-20 Taiho Pharmaceutical Co., Ltd. Indazole compound or salt thereof
SG11202104243VA (en) * 2018-12-06 2021-05-28 Daiichi Sankyo Co Ltd Cycloalkane-1,3-diamine derivative
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
US11572369B2 (en) * 2019-02-01 2023-02-07 University Of South Carolina Bicyclic pyridine compositions and methods of using the same for cancer therapy
SG11202113129UA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
SG11202113154YA (en) 2019-05-31 2021-12-30 Ikena Oncology Inc Tead inhibitors and uses thereof
CN112116960B (zh) * 2019-06-20 2024-10-11 中国石油化工股份有限公司 柴油加氢反应的组分含量确定方法、装置
WO2021067215A1 (en) 2019-09-30 2021-04-08 Agios Pharmaceuticals, Inc. Piperidine compounds as menin inhibitors
US11697657B2 (en) 2019-10-28 2023-07-11 Merck Sharp & Dohme Llc Small molecule inhibitors of KRAS G12C mutant
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
EP4067343A4 (en) 2019-11-29 2024-01-03 Taiho Pharmaceutical Co., Ltd. NEW PHENOLIC COMPOUND OR SALT THEREOF
IL293965A (en) 2019-12-19 2022-08-01 Janssen Pharmaceutica Nv History of Spiro straight chain transformed
CN111297863B (zh) * 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
TW202204334A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
TW202204333A (zh) 2020-04-08 2022-02-01 美商阿吉歐斯製藥公司 Menin抑制劑及治療癌症之使用方法
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
US20230405008A1 (en) * 2020-10-21 2023-12-21 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
BR112023023154A2 (pt) 2021-05-08 2024-01-23 Janssen Pharmaceutica Nv Derivados espiro substituídos
KR20240005747A (ko) 2021-05-08 2024-01-12 얀센 파마슈티카 엔브이 치환된 스피로 유도체
IL308476A (en) 2021-05-14 2024-01-01 Syndax Pharmaceuticals Inc Inhibitors of the menin-mil interaction
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
US20250333421A1 (en) 2021-06-03 2025-10-30 Janssen Pharmaceutica Nv Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
AU2022292697A1 (en) 2021-06-17 2024-02-01 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
CN115515958B (zh) * 2021-08-04 2023-09-29 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023011446A1 (zh) * 2021-08-04 2023-02-09 成都苑东生物制药股份有限公司 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
CA3244647A1 (en) * 2021-12-31 2025-06-13 Hitgen Inc. MENINO-MLL INHIBITOR AND ITS USE
WO2023215354A1 (en) * 2022-05-03 2023-11-09 Board Of Regents, The University Of Texas System Menin proteolysis targeting chimeras (protacs)
AU2023385514A1 (en) 2022-11-24 2025-07-10 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
CN116199633B (zh) * 2022-12-27 2024-05-31 甘肃省化工研究院有限责任公司 一种制备瑞维鲁胺的方法
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115741B2 (en) 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1947103A1 (en) * 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
AU2009291783A1 (en) * 2008-09-10 2010-03-18 Alcon Research, Ltd Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
WO2011014128A1 (en) * 2009-07-30 2011-02-03 National University Of Singapore Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity
EP2473054B1 (en) * 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
GB201114212D0 (en) * 2011-08-18 2011-10-05 Ucb Pharma Sa Therapeutic agents
CA2904612A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

Also Published As

Publication number Publication date
BR112015022602A2 (pt) 2017-07-18
US9505782B2 (en) 2016-11-29
US20160137665A1 (en) 2016-05-19
JP2016512514A (ja) 2016-04-28
US9216993B2 (en) 2015-12-22
WO2014164543A1 (en) 2014-10-09
EP2968342A4 (en) 2016-07-27
EP2968342A1 (en) 2016-01-20
CN105188705A (zh) 2015-12-23
JP2018115214A (ja) 2018-07-26
US20140275070A1 (en) 2014-09-18
US10160769B2 (en) 2018-12-25
IL241193A0 (en) 2015-11-30
US20170253611A1 (en) 2017-09-07
AU2014249233A1 (en) 2015-09-24
JP6670885B2 (ja) 2020-03-25
EP2968342B1 (en) 2018-10-03
US9505781B2 (en) 2016-11-29
CA2904612A1 (en) 2014-10-09
MX2015011576A (es) 2016-05-16
US20160046647A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
KR20150130389A (ko) 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법
CN113874374B (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
TWI436986B (zh) 新穎之２環性雜環化合物
CN101952259B (zh) 苯并二氮杂*化合物及药物组合物
CN112739690A (zh) 用作smarca2拮抗剂的吡啶-2-酮化合物
JP7627966B2 (ja) Ｃｄ７３阻害剤、その製造方法と応用
RS63603B1 (sr) Sredstva za indukciju apoptoze
JP2018024670A (ja) キナーゼ活性の阻害剤
WO2015127872A1 (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
TW202322796A (zh) 靶向p53突變體的化合物
EP2739618A1 (en) Quinazoline compounds as serine/threonine kinase inhibitors
WO2022216644A1 (en) Pyridinyl substituted oxoisoindoline compounds
KR20220054307A (ko) 암의 치료를 위한 1,2,4-옥사디아졸-5-온 유도체
CN117321051A (zh) 作为parp抑制剂的化合物
CN114206861A (zh) 用作ripk1抑制剂的稠环杂芳基化合物
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
CN118434417A (zh) 环状磺酰胺核糖核苷酸还原酶(rnr)抑制剂及其用途
JP2024540264A (ja) ゴナドトロピン放出ホルモン拮抗剤及びその調製方法並びに使用
CN120774901A (zh) Polθ抑制剂及其药物组合物和应用
WO2025247178A1 (zh) 一类prmt5抑制剂及其组合物和用途
TWI423974B (zh) 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
CN115515958A (zh) 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151007

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid